Susan Byrne

Title: Susan Byrne: Innovator in Anti-CCT5 Binding Molecules

Introduction

Susan Byrne is a prominent inventor based in Seattle, WA (US). She has made significant contributions to the field of biotechnology, particularly in the development of anti-CCT5 binding molecules. Her work has the potential to impact therapeutic approaches in cancer treatment.

Latest Patents

Susan Byrne holds a patent for "Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same." This patent includes CCT5-binding molecules, such as anti-CCT5 antibodies and antigen-binding fragments. These molecules are designed to specifically bind to CCT5 and include various forms like heavy chain variable (VH) regions and single-chain antibody fragments. The patent also covers conjugates that comprise these anti-CCT5 binding molecules, including immunoconjugates and antibody-drug conjugates, as well as chimeric receptors like chimeric antigen receptors (CARs). Additionally, genetically engineered cells expressing these CARs or CCT5-binding molecules are provided, with applications in adoptive cell therapy.

Career Highlights

Susan Byrne is currently associated with Juno Therapeutics GmbH, where she continues her innovative work in the field. Her research focuses on advancing therapeutic strategies that utilize her patented technologies.

Collaborations

She collaborates with notable colleagues, including Richard Sullivan and Francois Vigneault, who contribute to her research endeavors.

Conclusion

Susan Byrne is a key figure in the development of anti-CCT5 binding molecules, with her patent holding promise for future cancer therapies. Her work exemplifies the intersection of innovation and biotechnology, paving the way for advancements in medical treatments.